---
title: "Urogen Pharma General Counsel Jason Drew Smith Disposes of Common Shares"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/275651690.md"
datetime: "2026-02-11T19:55:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275651690.md)
  - [en](https://longbridge.com/en/news/275651690.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275651690.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/275651690.md) | [English](https://longbridge.com/en/news/275651690.md)


# Urogen Pharma General Counsel Jason Drew Smith Disposes of Common Shares

Jason Drew Smith, General Counsel of Urogen Pharma Ltd., reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Urogen Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-003778), on February 11, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### 相關股票

- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [iShares US Pharma (IHE.US)](https://longbridge.com/zh-HK/quote/IHE.US.md)
- [Urogen Pharma (URGN.US)](https://longbridge.com/zh-HK/quote/URGN.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-HK/quote/XLV.US.md)
- [VG Health (VHT.US)](https://longbridge.com/zh-HK/quote/VHT.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md)

## 相關資訊與研究

- [Prelude Therapeutics reports $99.5 mln net loss for 2025](https://longbridge.com/zh-HK/news/278542482.md)
- [Galecto Rebrands as Damora Therapeutics with New Ticker](https://longbridge.com/zh-HK/news/278556054.md)
- [Acurx Pharmaceuticals Q4 net loss narrows on lower R&D spend](https://longbridge.com/zh-HK/news/279032442.md)
- [Spruce Biosciences 2025 net loss narrows, secures $50 mln funding](https://longbridge.com/zh-HK/news/278380208.md)
- [Vertex's kidney disease drug meets main goal in late-stage trial](https://longbridge.com/zh-HK/news/278442392.md)